engleski

Platelet serotonin and MAO-B acitvity in Alzheimer's disease

Post mortem brain studies indicated that serotonin (5-hydroxytryptamine, 5-HT) could be involved in the ethiology of Alzheimer's disease (AD). The aim of the study was to determine platelet 5-HT concentration and platelet monoamine oxidase type B (MAO-B) activity in patients with early-onset AD and late-onset AD and in healthy subjects. The diagnosis of the probable Alzheimer's disease (NINCDS-ADRDA criteria) was established by two psychiatrists, according to ICD-10 and DSM-IV-TR criteria. The study included 42 patients with AD (20 men ; 22 women) and 75 healthy controls (36 men ; 39 women). In 22 patients (15 men, 7 women) the symptoms of early-onset AD (before the age of 65 years ; range 50-65 years) was observed. Late-onset AD was detected in 20 patients (5 men, 15 women) with age range from 67 to 88 years. Platelet 5-HT concentration and platelet MAO activity were determined spectrofluorimetrically. All participants gave their informed consent. Data were evaluated using one-way analysis of variance (ANOVA) followed by Newman-Keuls t-test. There was no sex related difference in platelet 5-HT concentration between patients with AD and healthy controls. Patients with early-onset AD had similar platelet 5-HT values as sex matched patients with late-onset AD and healthy controls. Significant (F=7.67 ; df=3, 113 ; p<0.001, ANOVA) difference in platelet MAO-B activity was observed between groups, with higher platelet MAO-B activity in female patients with AD than in healthy women (p<0.05 Newman-Keuls). A significant difference (F=5, 09 ; df=5, 111 ; p<0.001, ANOVA) in platelet MAO-B activity was found between patients with early and late-onset AD and healthy controls. The highest values (p<0.05 Newman-Keuls) of platelet MAO-B activity were found in female patients with late-onset of AD when compared to corresponding healthy controls. The results from our preliminary, ongoing study, support the presumption that platelet MAO-B activity could be used as a biological marker for different categories of AD.

early-onset Alzheimer's disease (AD); late-onset AD; platelet serotonin; platelet MAO

nije evidentirano